Chinese biophysicist Rao Zhihe has been appointed the first strategic scientist at an innovation hub that's expanding collaboration between China and Thailand on health and life sciences—a move underscoring how cross-border scientific partnerships can accelerate the hunt for treatments that benefit populations across Asia and beyond.
Rao has been working on natural anti-Covid products alongside researchers at Mahidol University. Early in the coronavirus pandemic, he and his team identified two parts of the virus that could be targeted by drugs and immediately shared the information with scientists around the world. "We shared them with more than 300 universities, research institutes and companies that approached our team before the findings were published," Rao said in an interview in Bangkok last month on his first trip abroad in three years.
The decision to share critical viral data freely, before publication, reflects a recognition that pandemic preparedness isn't a competitive advantage to be hoarded—it's a collective responsibility. Rao, a professor at Tsinghua and ShanghaiTech universities, framed this work as part of a larger imperative: developing defenses against future outbreaks that don't respect borders.
The Case for Broad-Spectrum Defense
During a forum with industry and university leaders on how biomedical research partnerships in the Asia-Pacific region could help prevent the next pandemic, Rao emphasized that the world "desperately" needed a broad-spectrum and effective antiviral drug—exactly what his team is working toward. "Joint efforts from international scientists were key," he told attendees at the forum, organized by the Association of Pacific Rim Universities.
This framing matters. It positions pandemic preparedness not as a national competition but as a shared vulnerability requiring coordinated, transparent research. When scientists withhold findings to gain patent advantage or geopolitical leverage, they slow the development of treatments that could save lives in multiple countries simultaneously.
Regional Cooperation Takes Shape
Rao's appointment as strategic scientist signals institutional commitment to deepening ties between China and Thailand on these questions. "I believe China and Thailand have good room for cooperation," he said. The innovation hub itself represents a practical recognition that health threats in Asia require solutions developed through collaboration, not isolation.
The forum brought together industry and university leaders to discuss cross-border biomedical research partnerships across the Asia-Pacific region. The gathering reflected a growing understanding that the next pandemic—and there will be one—will require research infrastructure, funding, and talent distributed across multiple countries, with incentive structures that reward sharing over secrecy.
Why This Matters:
Pandemic preparedness remains underfunded relative to its stakes. Most countries invest heavily in response after outbreaks occur, but far less in the upstream research needed to prevent them or limit their spread. When scientists like Rao share viral data with 300 institutions before publication, they're operating against the grain of academic incentive systems that reward individual credit and institutional prestige. The China-Thailand collaboration signals that some institutions are choosing differently—prioritizing public health outcomes over competitive advantage. For populations across Asia and globally, this approach to cross-border research partnerships could mean the difference between a novel pathogen becoming endemic and one being contained. It also raises a question for other nations: are their research institutions structured to reward this kind of transparency, or do they penalize scientists who prioritize collective welfare over institutional glory?